Skip to content

Study · Systematic review · 2023

2 results

Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.

Nauck MA, Mirna AEA, Quast DR

Diabetes, obesity & metabolism8 Feb 2023Cited by 28 (Europe PMC)

PMID36700380 (opens in a new tab)DOI10.1111/dom.14988 (opens in a new tab)PepBankPUB-36700380
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In patients with type 2 diabetes, tirzepatide lowered HbA1c more than basal insulin (pooled doses, difference -0.90%).

    In plain wordsIn people with type 2 diabetes, tirzepatide lowered blood sugar (HbA1c) more than basal insulin.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c reduction versus basal insulin
    Study

    n: not reported in source

    Comparator
    Basal insulin
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    pooled dosesAs given in this study (human).

    Measurements

    Difference in HbA1c reduction
    −0.9%
    tirzepatide pooled doses vs basal insulin

    Source sentences

    Summary
    the only GIP/GLP-1 receptor co-agonist, tirzepatide (pooled doses; ΔHbA1c -0.90 [-1.06; -0.75]%)
    1 context sentence
    Summary · context
    We performed an updated meta-analysis of randomized clinical trials of head-to-head comparisons of IBGLMs (short- and long-acting glucagon-like peptide-1 [GLP-1] receptor agonists [GLP-1RAs] and glucose-dependent insulinotropic polypeptide [GIP]/GLP-1 receptor co-agonist tirzepatide) versus basal in…
  2. 02HumanSystematic reviewEfficacy outcome

    In patients with type 2 diabetes, tirzepatide lowered body weight more than basal insulin (-12.0 kg).

    In plain wordsIn people with type 2 diabetes, tirzepatide led to more weight loss than basal insulin.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight versus basal insulin
    Study

    n: not reported in source

    Comparator
    Basal insulin
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Difference in body weight
    −12 kg
    tirzepatide vs basal insulin

    Source sentences

    Summary
    in particular tirzepatide (-12.0 [-13.8; -10.1] kg)
    1 context sentence
    Summary · context
    We performed an updated meta-analysis of randomized clinical trials of head-to-head comparisons of IBGLMs (short- and long-acting glucagon-like peptide-1 [GLP-1] receptor agonists [GLP-1RAs] and glucose-dependent insulinotropic polypeptide [GIP]/GLP-1 receptor co-agonist tirzepatide) versus basal in…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.